Please assess the completion status of the following clinical trial:

Trial Title: A Study Run At Multiple Study Sites to Test Whether the SAMANTA Questionnaire That is Used to Diagnose Heavy Menstrual Bleeding (HMB), Can Also Be Used to Assess Changes of Severity of HMB in Women with HMB Who Are Treated During 12 Months with a Chronic Hormonal Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Women in childbearing age, ≥18 years old, not intending to become pregnant during the next year.~* Women diagnosed with heavy menstrual bleeding or idiopathic menorrhagia according to medical criteria and based on clinical judgment.~* Women for whom the clinician decides, in agreement with the patient, to prescribe any of the available chronic hormonal treatments with the therapeutic indication of HMB in Spain (Mirena, Qlaira or Progevera).~* Women capable of reading and writing.~* Women who signed the informed consent.~Exclusion Criteria:~* Women with amenorrhea or menopause.~* Women with contraindications and warnings with the chronic hormonal treatment prescribed for HMB as per the summary of product characteristics (interaction with concomitant medication, etc.).~* Women receiving contraceptive hormonal therapy or using a copper intrauterine device.~* Women on hormone replacement therapy.~* Women with a history of malignancy.~* Women with degenerative diseases that could directly negatively impact their daily life.~* Women who have given birth within the previous 6 months.~* Women who are pregnant.~* Women participating in an investigational program with interventions outside of routine clinical practice.~* Women with psychiatric disorders who are unable to make decisions and follow instructions.~* Women with concomitant medication that may lead to changes in the bleeding pattern (e.g. antiplatelet and/ or anticoagulants).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Women with HMB (Type: None): Women with a diagnostic of HMB according to medical criteria and based on clinical judgment that have freely chosen a chronic hormonal treatment under therapeutic indication of HMB in Spain

Based on this trial design, predict the completion outcome and termination type (if applicable).